Gina Roberts folds up blankets on her bed in the sober home where she’s been living in Providence, R.I. on Feb. 2. She has ...

GoodRx reports that the FDA has approved oral semaglutide (Wegovy) for weight loss, offering an alternative to injections ...

Other research has since tied GLP-1 receptor agonists to other eye conditions, including age-related macular degeneration and ...

Now, Chinese pharmaceutical company Shanghai Shiling Pharmaceutical has announced it is trialing a semaglutide nasal spray, ...

New Medicaid prior-authorization rules have advocates in Connecticut concerned about patients losing access to their ...

Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript February 11, 2026 Veru Inc. beats earnings expectations. Reported EPS is $-0.26254, expectations were $-0.47. Operator: Good morning, ladies ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation ...

October, the company announced that it is withdrawing the financial targets communicated on 1 June 2022. The targets are currently under revision ...

Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.

Q4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon- CNP under FDA ...

Novo Nordisk sued Hims and Hers Health on Monday over patent infringement after the U. telehealth firm launched, then ...

Once-weekly CagriSema significantly reduced HbA1c and body weight vs semaglutide in patients with type 2 diabetes in the REIMAGINE 2 trial.